Silver Oak Securities Incorporated Purchases New Stake in DexCom, Inc. (NASDAQ:DXCM)

Silver Oak Securities Incorporated purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,730 shares of the medical device company's stock, valued at approximately $456,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Proficio Capital Partners LLC bought a new stake in DexCom during the 4th quarter worth about $5,812,000. Golden State Wealth Management LLC raised its holdings in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in DexCom during the 4th quarter worth about $49,000. Farther Finance Advisors LLC raised its holdings in DexCom by 29.3% during the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC raised its holdings in DexCom by 34.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after purchasing an additional 1,333 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at approximately $7,874,445.60. This represents a 0.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $85.06, for a total value of $124,697.96. Following the completion of the sale, the executive vice president directly owned 108,155 shares of the company's stock, valued at approximately $9,199,664.30. The trade was a 1.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Up 0.5%

NASDAQ:DXCM traded up $0.46 during trading hours on Monday, reaching $83.39. 434,674 shares of the stock were exchanged, compared to its average volume of 4,397,570. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The firm has a 50 day moving average of $83.26 and a 200 day moving average of $79.85. The stock has a market cap of $32.70 billion, a PE ratio of 62.12, a PEG ratio of 1.77 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's revenue was up 12.5% compared to the same quarter last year. During the same period last year, the company earned $0.32 EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DXCM. Robert W. Baird dropped their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Piper Sandler dropped their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group assumed coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Citigroup reaffirmed a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Finally, Truist Financial assumed coverage on DexCom in a research note on Monday, June 16th. They issued a "buy" rating and a $102.00 price target for the company. Five analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.